trial · primary record
Pembrolizumab
Anaplastic Large Cell Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 13 |
| Primary completion | 2027-02-18 |
| Primary endpoint | Number of Participants Who Had Dose Limiting Toxicities |
| Registry ID | NCT03598998 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:49.872Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03598998
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEMBROLIZUMAB · approval
- Pembrolizumab · compound